⌘K
t
Haleon plc announced its total voting rights and capital on 01 May 2026, as at 30 April 2026. The company reported 8,891,932,595 ordinary shares of £0.01 each were issued, of which 12,240,797 shares were held as treasury shares. This resulted in a total of 8,879,691,798 ordinary shares with voting rights.
| Date | 1 May 2026 |
| Time | 15:30:01 |
| Category | Capital structure |
| ID | 8675C |
Haleon plc: Total Voting Rights and Capital
01 May 2026: As at 30 April 2026 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,891,932,595 ordinary shares of £0.01 each, of which 12,240,797 are held as treasury shares.
Therefore, the number of ordinary shares with voting rights is 8,879,691,798 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.